focus -WSS

focus

author：focus 2025-08-26 23:46:39 - browse：998

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Sanders wants to replace patents with prizes for drug inventions

WSS

Extensive review finds private equity owners jack up cost of care

There’s a way to spot data fakery. All journals should be using it

Clinicians often fail to acknowledge the pain caused by long Covid

Scientists grapple with ethics of stem cell research

J&J reports mixed data on next

Delta passengers in Vegas fall sick while waiting on flight in triple

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Hollywood unions extend contract negotiations for actors

There’s a way to spot data fakery. All journals should be using it

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Hospitals need to get ahead of regulations on climate change

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Supreme Court strikes down use of affirmative action

Telehealth startups are trying to fill the menopause care vacuum

After affirmative action ruling, medical educators look to 'holistic review'

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

leisure time

Decentralized clinical trials need collaboration to achieve wider use

Lawsuit challenges CMS nursing home minimum staffing rule

Achieving telehealth equity for people with hearing loss

Unmasking the 'centricity' illusion in clinical trials

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Extensive review finds private equity owners jack up cost of care

hotspot

focus

focus

knowledge